Home Excelencia Severo Ochoa
Patents
  1. PCT/GB2008/002504 Registrada en 21/07/2008. Publicación nº: WO/2009/013484 (29/01/2009) Título: Immune modulation via C-type lectin. Inventores: Sancho D, Reis e Sousa C, Joffre OP, Rogers N, Schulz O, Pennington D. Holder Entity: Cancer Research UK. Compañía que lo licencia: Cancer Research technology limited.

     

  2. PCT/ES2005/000019. Registrada en 17/01/2005. Publicación nº: WO/2005/078081 (25/08/2005). Título: Use of compounds that regulate HDAC6 tubulin deacetylase activity. Inventores: Serrador J, Cabrero JR, Sancho D, Mittelbrunn M, Urzainqui A, Sanchez-Madrid F.

     

  3. PCT/US2004/002864. Registrada en 02/02/2004. Publicación nº: WO/2004/069183 (19/08/2004) Título: Immune regulation based on the targeting of early activation molecules. Inventores: Sancho D, Esplugues E, Vega-Ramos J, Engel P, Martínez-A C, Lauzurica P, and Sánchez-Madrid F. Entidad propietaria: Madrid Autonomous University. Compañía que lo licencia: Albor Biologics Inc.
David_Sancho
  • David Sancho Madrid
  • Junior group leader
  • Ext.2010

David Sancho graduated in Biology at the University of Murcia, Spain (1995) and pursued a research career while specializing in Immunology through the Spanish National Health System program at the Hospital de la Princesa, Madrid (2000). The subject of his PhD thesis (Universidad Autónoma de Madrid, 2003) was the function of the C-type lectin CD69, with special emphasis on models of inflammation. During his postdoc tenure at the London Research Institute, (Cancer Research UK, 2004-2009) he discovered a new C-type lectin receptor specific to dendritic cells (CLEC9A, DNGR-1) that was subsequently used for targeted anti-tumor vaccination. Through the generation of CLEC9A deficient mice, he found that this receptor is involved in the generation of immunity associated with dead cells. This work has possible implications in the origins of chronic inflammation and autoimmunity. He joined the CNIC in September 2009.